Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.46 USD | -5.32% |
|
+21.13% | +98.45% |
06-27 | BMO Initiates Neurogene at Outperform With $65 Price Target | MT |
06-18 | Neurogene Doses First Patient in High-Dose Group of Rett Syndrome Trial | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+98.45% | 527M | |
+17.72% | 44.44B | |
-10.33% | 37.99B | |
+37.55% | 37.75B | |
+29.36% | 30.78B | |
-8.44% | 27.38B | |
+12.45% | 26.17B | |
+44.19% | 14.15B | |
+31.93% | 12.59B | |
-7.67% | 11.28B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- BMO Initiates Neurogene at Outperform With $65 Price Target